Wang Zhigang, Luo Yong, Chen Lvan, Liang Wu
Department of Neurosurgery, The First People's Hospital of Jingmen, Jingmen, Hubei 448000, P.R. China.
Exp Ther Med. 2017 Jun;13(6):3613-3618. doi: 10.3892/etm.2017.4423. Epub 2017 May 4.
Neural stem cell (NSC) therapy is a promising treatment for traumatic brain injury (TBI). In addition, mesenchymal stem cells (MSCs) have been investigated for the treatment of TBI due to their functions in neural regeneration and their neurotrophic effect. In the present study, the safety, feasibility and biological effects of autologous MSC-derived NSC-like cell transplantation were investigated in 10 patients with severe TBI. All patients received intravenous or intrathecal injections of human NSC-like cells and were evaluated with physical and neurological examinations, routine laboratory tests and neuroradiological findings. The results indicated that the majority of patients experienced improved neurological function in different degrees during the follow-up period. No mortality or serious adverse events were observed in any patient subsequent to transplantation. Higher serum levels of nerve growth factor and brain-derived neurotrophic factor were detected following the transplantation, as compared with the levels prior to treatment. Overall, the present results suggest that transplantation of autologous NSC-like cells is feasible and appears to be safe for the treatment of non-acute severe TBI.
神经干细胞(NSC)疗法是一种很有前景的创伤性脑损伤(TBI)治疗方法。此外,间充质干细胞(MSC)因其在神经再生中的作用及其神经营养作用,也被研究用于TBI的治疗。在本研究中,对10例重度TBI患者进行了自体MSC来源的神经干细胞样细胞移植的安全性、可行性和生物学效应研究。所有患者均接受了静脉或鞘内注射人神经干细胞样细胞,并通过体格检查、神经学检查、常规实验室检查和神经放射学检查进行评估。结果表明,大多数患者在随访期间神经功能有不同程度的改善。移植后未观察到任何患者死亡或出现严重不良事件。与治疗前相比,移植后检测到血清神经生长因子和脑源性神经营养因子水平升高。总体而言,目前的结果表明,自体神经干细胞样细胞移植对于非急性重度TBI的治疗是可行的,且似乎是安全的。